Replies to post #206076 on Biotech Values

[dewophile]

There are about a million pts on dialysis between the 3 major markets US EU JPN so figure 100k addressable pts for whom sovaldi based regimens cannot be used. I figure mrk and Abbv will likely split these pretty evenly